Roflumilast, as a PDE4 inhibitor, primarily known for its role in treating chronic obstructive pulmonary disease (COPD), could be a valuable therapeutic agent in cancer treatment, especially in specific types like B-cell malignancies and lung cancer [19, 20]. This evidence concerns the gene PDE4A and lung carcinoma.